Synapse - Center for Hematologic Malignancies

Results (13546)

Vascular endothelial-cadherin targeted alpha-particle mediated vascular killing and remodeling augments subsequent chemotherapeutic efficacy

Meeting Abstract

Escorcia, F. E.; Henke, E.; McDevitt, M. R.; Villa, C.; Smith-Jones, P.; Blasberg, R.; Benezra, R.; Scheinberg, D. A.
Blood (2009)

Fulltext@MSK | Save

Initial remission duration of less than 1 year is no longer an adverse prognostic factor for patients with relapsed HL undergoing high dose therapy and autologous stem cell transplant: Results of a combined analysis from two large transplant centers

Meeting Abstract

Moskowitz, A. J.; Sweetenham, J.; Bolwell, B. J.; Maragulia, J. C.; Vanak, J. M.; Moskowitz, C. H.; Smith, S.
Blood (2009)

Fulltext@MSK | Save

Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events

Meeting Abstract

McCarthy, P. L.; Owzar, K.; Stadtmauer, E. A.; Giralt, S.; Hurd, D. D.; Hassoun, H.; Hofmeister, C.; Richardson, P.; Weisdorf, D. J.; Pasquini, M. C.; more...
Blood (2009)

Fulltext@MSK | Save

Stem cell transplant (SCT) and pralatrexate therapy: Outcome of patients with relapsed or refractory peripheral T-cell lymphoma who received SCT prior to or following pralatrexate therapy

Meeting Abstract

Popplewell, L.; Pro, B.; Jacobsen, E.; Horwitz, S. M.; Boyd, A.; Patterson, M.; Fruchtman, S.; O'Connor, O. A.
Blood (2009)

Fulltext@MSK | Save

Disease-free survival after cord blood (CB) transplantation is not different to that after related or unrelated donor transplantation in patients with hematologic malignancies

Meeting Abstract

Ponce, D.; Zheng, J.; Gonzales, A. M.; Castro-Malaspina, H. R.; Hsu, K. C.; Jakubowski, A.; Jenq, R. R.; Koehne, G.; Papadopoulos, E. B.; Perales, M. A.; more...
Blood (2009)

Fulltext@MSK | Save

Clinical implementation of a novel high-throughput screen of primary leukemia cells to customize therapy for relapsed/refractory acute myeloid leukemia (AML)